These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 39226091)

  • 1. Impact of Long SARS-CoV-2 Omicron Infection on the Health Care Burden: Comparative Case-Control Study Between Omicron and Pre-Omicron Waves.
    Valdivieso-Martinez B; Lopez-Sanchez V; Sauri I; Diaz J; Calderon JM; Gas-Lopez ME; Lidon L; Philibert J; Lopez-Hontangas JL; Navarro D; Cuenca L; Forner MJ; Redon J
    JMIR Public Health Surveill; 2024 Sep; 10():e53580. PubMed ID: 39226091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients.
    Taquet M; Sillett R; Zhu L; Mendel J; Camplisson I; Dercon Q; Harrison PJ
    Lancet Psychiatry; 2022 Oct; 9(10):815-827. PubMed ID: 35987197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 infection following booster vaccination: Illness and symptom profile in a prospective, observational community-based case-control study.
    Antonelli M; Penfold RS; Canas LDS; Sudre C; Rjoob K; Murray B; Molteni E; Kerfoot E; Cheetham N; Pujol JC; Polidori L; May A; Wolf J; Modat M; Spector T; Hammers A; Ourselin S; Steves C
    J Infect; 2023 Dec; 87(6):506-515. PubMed ID: 37777159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers.
    Ali AM; Tofiq AM; Rostam HM; Ali KM; Tawfeeq HM
    J Med Virol; 2022 Dec; 94(12):5867-5876. PubMed ID: 36029103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study.
    Yung CF; Pang D; Kam KQ; Lye DC; Ong B; Chong CY; Tan KB
    Lancet Child Adolesc Health; 2023 Jul; 7(7):463-470. PubMed ID: 37201540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021.
    León TM; Dorabawila V; Nelson L; Lutterloh E; Bauer UE; Backenson B; Bassett MT; Henry H; Bregman B; Midgley CM; Myers JF; Plumb ID; Reese HE; Zhao R; Briggs-Hagen M; Hoefer D; Watt JP; Silk BJ; Jain S; Rosenberg ES
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):125-131. PubMed ID: 35085222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postacute symptoms 4 months after SARS-CoV-2 infection during the Omicron period: a nationwide Danish questionnaire study.
    Spiliopoulos L; Sørensen AIV; Bager P; Nielsen NM; Hansen JV; Koch A; Meder IK; Videbech P; Ethelberg S; Hviid A
    Am J Epidemiol; 2024 Aug; 193(8):1106-1114. PubMed ID: 37981717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maternal and perinatal outcomes of SARS-CoV-2 infection in unvaccinated pregnancies during Delta and Omicron waves.
    Birol Ilter P; Prasad S; Mutlu MA; Tekin AB; O'Brien P; von Dadelszen P; Magee LA; Tekin S; Tug N; Kalafat E; Khalil A
    Ultrasound Obstet Gynecol; 2022 Jul; 60(1):96-102. PubMed ID: 35441407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
    Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
    JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 Infection and Hospitalization Among Adults Aged ≥18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance - Los Angeles County, California, November 7, 2021-January 8, 2022.
    Danza P; Koo TH; Haddix M; Fisher R; Traub E; OYong K; Balter S
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(5):177-181. PubMed ID: 35113851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 Reinfections in Health-Care Workers, 1 March 2020-31 January 2023.
    Cegolon L; Magnano G; Negro C; Larese Filon F;
    Viruses; 2023 Jul; 15(7):. PubMed ID: 37515237
    [No Abstract]   [Full Text] [Related]  

  • 12. Event rates and incidence of post-COVID-19 condition in hospitalised SARS-CoV-2 positive children and young people and controls across different pandemic waves: exposure-stratified prospective cohort study in Moscow (StopCOVID).
    Pazukhina E; Rumyantsev M; Baimukhambetova D; Bondarenko E; Markina N; El-Taravi Y; Petrova P; Ezhova A; Andreeva M; Iakovleva E; Bobkova P; Pikuza M; Trefilova A; Abdeeva E; Galiautdinova A; Filippova Y; Bairashevskaia A; Zolotarev A; Bulanov N; DunnGalvin A; Chernyavskaya A; Kondrikova E; Kolotilina A; Gadetskaya S; Ivanova YV; Turina I; Eremeeva A; Fedorova LA; Comberiati P; Peroni DG; Nekliudov N; Genuneit J; Reyes LF; Brackel CLH; Mazankova L; Miroshina A; Samitova E; Borzakova S; Carson G; Sigfrid L; Scott JT; McFarland S; Greenhawt M; Buonsenso D; Semple MG; Warner JO; Olliaro P; Osmanov IM; Korsunskiy AA; Munblit D;
    BMC Med; 2024 Feb; 22(1):48. PubMed ID: 38302974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoimmune Sequelae After Delta or Omicron Variant SARS-CoV-2 Infection in a Highly Vaccinated Cohort.
    Wee LE; Lim JT; Tay AT; Chiew CJ; Ong B; Lye DCB; Lahiri M; Tan KB
    JAMA Netw Open; 2024 Aug; 7(8):e2430983. PubMed ID: 39212988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study.
    Pinato DJ; Aguilar-Company J; Ferrante D; Hanbury G; Bower M; Salazar R; Mirallas O; Sureda A; Plaja A; Cucurull M; Mesia R; Townsend S; Jackson A; Dalla Pria A; Newsom-Davis T; Handford J; Sita-Lumsden A; Apthorp E; Vincenzi B; Bertuzzi A; Brunet J; Lambertini M; Maluquer C; Pedrazzoli P; Biello F; Sinclair A; Bawany S; Khalique S; Rossi S; Rogers L; Murphy C; Belessiotis K; Carmona-García MC; Sharkey R; García-Illescas D; Rizzo G; Perachino M; Saoudi-Gonzalez N; Doonga K; Fox L; Roldán E; Gaidano G; Ruiz-Camps I; Bruna R; Patriarca A; Martinez-Vila C; Cantini L; Zambelli A; Giusti R; Mazzoni F; Caliman E; Santoro A; Grosso F; Parisi A; Queirolo P; Aujayeb A; Rimassa L; Prat A; Tucci M; Libertini M; Grisanti S; Mukherjee U; Diamantis N; Fusco V; Generali D; Provenzano S; Gennari A; Tabernero J; Cortellini A;
    Lancet Oncol; 2022 Jul; 23(7):865-875. PubMed ID: 35660139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022.
    Modes ME; Directo MP; Melgar M; Johnson LR; Yang H; Chaudhary P; Bartolini S; Kho N; Noble PW; Isonaka S; Chen P
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(6):217-223. PubMed ID: 35143466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study.
    Nyberg T; Ferguson NM; Nash SG; Webster HH; Flaxman S; Andrews N; Hinsley W; Bernal JL; Kall M; Bhatt S; Blomquist P; Zaidi A; Volz E; Aziz NA; Harman K; Funk S; Abbott S; ; Hope R; Charlett A; Chand M; Ghani AC; Seaman SR; Dabrera G; De Angelis D; Presanis AM; Thelwall S
    Lancet; 2022 Apr; 399(10332):1303-1312. PubMed ID: 35305296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nationwide Effectiveness of First and Second SARS-CoV2 Booster Vaccines During the Delta and Omicron Pandemic Waves in Hungary (HUN-VE 2 Study).
    Kiss Z; Wittmann I; Polivka L; Surján G; Surján O; Barcza Z; Molnár GA; Nagy D; Müller V; Bogos K; Nagy P; Kenessey I; Wéber A; Pálosi M; Szlávik J; Schaff Z; Szekanecz Z; Müller C; Kásler M; Vokó Z
    Front Immunol; 2022; 13():905585. PubMed ID: 35812442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
    Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
    Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
    PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study.
    Tan CY; Chiew CJ; Pang D; Lee VJ; Ong B; Lye DC; Tan KB
    Lancet Infect Dis; 2023 Jul; 23(7):799-805. PubMed ID: 36924786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.